Effect of miR-26a on drug resistance of chronic lymphocytic leukemia cells by regulating PTEN gene

Abstract

Abstract: Objective To observe the regulation of microRNA-26a (miR-26a) on the drug resistance of chronic lymphocyte leukemia (CLL) cells through the phosphatase and tensin homolog deleted on chromosome ten (PTEN). Methods The experiment was divided into 4 groups: control group (L1210 cells), resistance group (L1210/DDP cells), NC group (transfected with empty plasmid+L1210/DDP cells), inhibitor group (transfected with miR-26a-inhibitor plasmid+L1210/DDP and inhibitor group (transfected with miR-26a-inhibitor plasmid+L1210/DDP cells). miR-26a and PTEN mRNA expression were detected by RT-qPCR. Dual luciferase experiment was used to detect the targeting of miR-26a to PTEN. MTT method was used to detect cell resistance to cisplatin (DDP). Flow cytometry was used to detect cell apoptosis rates. Western blot was used to detect of PTEN, phosphatidyl inositol-3-kinase (PI3K), serine-threonine protein kinase (AKT) protein expressions in cells. Results miR-26a inhibited the expression of PTEN in cells (P＜0.05). miR-26a targeted PTEN. Inhibiting the expression of miR-26a reduced the IC₅₀ value of cells to DDP, increased the rates of apoptosis, and up-regulated the expression of PI3K protein and p-AKT/AKT (P＜0.05). Conclusions Inhibiting the expression of miR-26a can reduces the effect of cell resistance through up-regulating the expression of PTEN.

Key words: chronic lymphocyte leukemia, drug resistance, microRNA-26a, phosphatase and tensin homolog deleted on chromosome ten

CLC Number:

R733.72

MAO Hong-bin, HE Ming. Effect of miR-26a on drug resistance of chronic lymphocytic leukemia cells by regulating PTEN gene[J]. Basic & Clinical Medicine, 2021, 41(6): 871-875.

References

[1] Kipps TJ, Fraser G, Coutre SE, et al.Long-term studies assessing outcomes of ibrutinib therapy in patients with del(11q) chronic lymphocytic leukemia[J]. Clin Lymphoma Myeloma Leuk, 2019, 19:715-722.
[2] Liu YL, Yan ZX, Xia Y, et al. Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreas-ing fibrinogen gamma chain (FGG)expression[J]. Am J Cancer Res, 2020, 10:939-952.
[3] Liu J, Li X, Wang M, et al. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer[J]. Int J Oncol, 2018, 53:1601-1612.
[4] 徐芝立, 卢莉莉, 梁长春, 等. 肾透明细胞癌中PTEN分子的表达与预后关系[J]. 世界中医药, 2016, 11:2222-2223.
[5] 邹志建, 孙鸿丽, 沈云峰, 等. miR-214介导慢性淋巴细胞白血病对氟达拉滨耐药的作用研究[J]. 中国实验血液学杂志, 2019, 27:1395-1401.
[6] Tormo E, Adam-Artigues A, Ballester S, et al. The role of miR-26a and miR-30b in HER2⁺ breast cancer trastuzumab resistance and regulation of the CCNE2 gene[J]. Sci Rep, 2017, 7:41309. doi: 10.1038/srep41309.
[7] Xu S, Wang T, Yang Z, et al. miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13[J]. Oncotarget, 2016, 7:45687-45701.
[8] 吴玉婷, 马茜, 汤步富, 等. 氯化锂对第10号染色体缺失的磷酸酶及张力蛋白同源基因缺失肿瘤的疗效分析[J]. 中华医学杂志, 2019, 99:2362-2366.
[9] Ding S, Zheng Y, Xu Y, et al. miR-21/PTEN signaling modulates the chemo-sensitivity to 5-fluorouracil in human lung adenocarcinoma A549 cells[J]. Int J Clin Exp Pathol, 2019, 12:2339-2352.
[10] Sun H, Zhou X, Bao Y, et al. Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer[J]. Open Biol, 2019, 9:180227. doi: 10.1098/rsob.180227.
[11] Dong C, Chen Y, Ma J, et al. Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway[J]. Am J Cancer Res, 2020, 10:263-274.
[12] Liu T, Guo J, Zhang X. miR-202-5p/PTEN mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt signaling pathway[J]. Cancer Biol Ther, 2019, 20:989-998.
[13] Xu Y, Cheng M, Mi L, et al. miR-22-3p enhances the chemosensitivity of gastrointestinal stromal tumor cell lines to cisplatin through PTEN/PI3K/Akt pathway[J]. Iran J Allergy Asthma Immunol, 2018, 17:318-325.